RWE Committee Update


  • RWE Draft Guidance is complete. Industry consultation will last from March 13- April 3rd. If your organization would like to provide feedback, please coordinate a point person to reach out to Pauline Dong and Jennifer Carroll to acquire the draft document and collect feedback from your organization. We ask that all feedback be collated into a single response provided prior to the consultation deadline.

Please remember that this is a draft guidance. It should not be shared externally.


In November of 2022, PAAB struck a committee to generate a framework for acceptance of Real-World Evidence (RWE) in healthcare professional advertising. While the framework will focus on evidentiary standards and disclosure criteria pertaining to RWE, it will set the stage for guidance pertaining to other forms of evidence which don’t meet evidentiary gold standards but have value to clinical practice. The committee is dedicated to ensuring the framework promotes the use of RWE in advertising in a manner that is truthful, transparent, trustworthy, and in the best interest of all Canadians who rely on informed healthcare professionals.

The committee consists of industry experts from manufacturers and agencies.

Amyn Sayani Ph.D.

Director, Medical Evidence

Scientific Affairs

AstraZeneca Canada

Chrysanthy Christopoulous

Medical Advisor and Strategist 

Lemieux Bedard

Jefferson Tea

Vice-President, Medical & Scientific Affairs


Matt Slipek

Sr Planner, Strategic Planning


Manushvi Gupta

Regulatory Manager



Nina Hemery

Medical Advisor


Virginie Giroux

Director of HEOR






Patrick Massad – Commissioner


Pauline Dong - Director of Policy


Jennifer Carroll - Director of Communications


As the committee finalizes the draft document, we will head to industry consultation and consultation with healthcare professionals. Please stay tuned for further development and updates along the development timeline.



Do you have questions? We have answers!

Learn More


Powered by Innovasium